Michael J Birrer
Affiliation: National Institutes of Health
- Ovarian cancer: not a borderline issue!Michael J Birrer
National Institutes of Health, Bethesda, Maryland 20892, USA
Cancer Biol Ther 5:786-7. 2006
- Summary and discussion of session recommendationsJane Fountain
National Cancer Institute, Bethesda, MD 20892, USA
Gynecol Oncol 103:S23-5. 2006
- Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomasMichael J Birrer
Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Clin Oncol 25:2281-7. 2007..To identify markers that can predict overall survival in patients with high-grade advanced stage serous adenocarcinomas...
- Etiology and pathogenesis of epithelial ovarian cancerSamuel C Mok
Department of Obstetrics, Gynecology, and Reproductive Biology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Dis Markers 23:367-76. 2007..However, the link between all these genetic changes and the etiological factors remains to be established...
- Workshop on imaging science development for cancer prevention and preemptionGary J Kelloff
NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
Cancer Biomark 3:1-33. 2007..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
- The future of phase II trialsJohn Farley
Division of Gynecologic Oncology, Tripler Army Medical Center, 1 Jarrett White Road, TAMC 96859 5000, USA
Gynecol Oncol 103:S20-2. 2006
- Biomarker discovery in epithelial ovarian cancer by genomic approachesSamuel C Mok
Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Adv Cancer Res 96:1-22. 2007..These powerful techniques hold the potential to unravel the genetic origins of ovarian cancer. Hopefully, this will translate into earlier diagnosis and better patient outcome from disease...
- Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinomaChunhua Lu
Departments of Gynecologic Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 67:1757-68. 2007..The present study shows that tumor and normal endothelium differ at the molecular level, which may have significant implications for the development of antiangiogenic therapies...
- Biomarkers of mucinous tumors of the ovaryGoli Samimi
Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892, USA
Dis Markers 23:389-96. 2007
- Cell cycle and related proteinJohn Farley
Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences 4301 Jones Bridge Road, Bethesda, MD 20814, USA
Dis Markers 23:433-43. 2007
- Early events in the pathogenesis of epithelial ovarian cancerCharles N Landen
Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
J Clin Oncol 26:995-1005. 2008....
- Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasmsBehrang Litkouhi
Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
Gynecol Oncol 109:234-9. 2008..Microarray analysis previously demonstrated high CEACAM6 overexpression in MON's and this study sought to validate this finding...
- Genomic analysis of epithelial ovarian cancerJohn Farley
Department of Obstetrics and Gynecology, Uniformed Services University of Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
Cell Res 18:538-48. 2008..This review summarizes the new genomic data on epithelial ovarian cancers of different histology and grade and the impact it will have on our understanding and treatment of this disease...
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancerLin Zhang
Center for Research on Early Detection and Cure of Ovarian Cancer and Gynecology, Department of Obstetrics, University of Pennsylvania, Philadelphia, PA 19104, USA
Proc Natl Acad Sci U S A 105:7004-9. 2008..Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer...
- Classification of ovarian cancer: a genomic analysisMichael P Stany
Adv Exp Med Biol 622:23-33. 2008
- A gene signature predicting for survival in suboptimally debulked patients with ovarian cancerTomas Bonome
Cell and Cancer Biology Branch, National Cancer Institute, NIH, Rockville, Maryland 20892, USA
Cancer Res 68:5478-86. 2008..Ultimately, the prognostic classifier defined for suboptimally debulked tumors may aid in the classification and enhancement of patient outcome for this high-risk population...
- Biomarkers and clinical trial designJohn Farley
Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
Gynecol Oncol 103:S3-5. 2006
- CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potentialRamon G Manzano
Cell and Cancer Biology Department, National Cancer Institute, 9610 Medical Center Drive, Rockville, Maryland 20850, USA
Oncogene 21:4435-47. 2002..These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer...
- Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancerJan S Sunde
Walter Reed Army Medical Center, Washington, District of Columbia, USA
Cancer Res 66:8404-12. 2006..These results suggest that altered expression of these genes is responsible for disrupted TGF-beta signaling in ovarian cancer and they may be useful as new and novel therapeutic targets for ovarian cancer...
- Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group studyJohn Farley
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Tripler Army Medical Center TAMC, HI, 96859 5000, USA
Cancer Res 63:1235-41. 2003..006). High cyclin E expression was an independent poor prognostic factor for patients with advanced ovarian cancer, and it was associated with amplification of the cyclin E gene...
- Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studiesKristin K Zorn
Department of Cell and Cancer Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20850, USA
Clin Cancer Res 9:4811-8. 2003..Our purpose was to assess the impact of the use of different types of normal controls on the determination of gene expression alterations in ovarian cancer studies...
- Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cellsShengquan Liu
Department of Chemistry, Oklahoma State University, Stillwater, Oklahoma 74078 3071, USA
J Med Chem 47:999-1007. 2004..The growth inhibition was associated with cell loss and induction of reactive oxygen species...
- Current challenges and opportunities for research on borderline ovarian tumorsMark E Sherman
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892, USA
Hum Pathol 35:961-70. 2004....
- Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathwaysHoward Donninger
Department of Cell and Cancer Biology, National Cancer Institute, Rockville, MD 20850, USA
Oncogene 23:8065-77. 2004....
- Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovaryHiroshi Tsuda
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Oncology 67:291-9. 2004..The purpose of this study is to compare DNA, mRNA and protein levels of the cyclin E between clear cell (CC) and serous (SC) ovarian carcinomas, and evaluate the relationship between cyclin E and p53 status...
- Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platformHiroshi Tsuda
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, BLI 447, 221 Longwood Avenue, Boston, MA 02115, USA
Cancer Genet Cytogenet 155:97-107. 2004..These results show the feasibility of using the cDNA array platform to identify changes in DNA and mRNA copy number simultaneously in microdissected tumor tissues...
- p75-Ras-GRF1 is a c-Jun/AP-1 target protein: its up regulation results in increased Ras activity and is necessary for c-Jun-induced nonadherent growth of Rat1a cellsVirna D Leaner
National Cancer Institute, 9610 Medical Center Dr, Room 300, Rockville, MD 20850 3300, USA
Mol Cell Biol 25:3324-37. 2005..We conclude that c-Jun/AP-1 regulates endogenous p75-Ras-GRF1 expression and that c-Jun/AP-1-regulated anchorage-independent cell growth requires activation of Ras-PI3K-AKT signal transduction...
- Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancersAmir A Jazaeri
Laboratory of Biosystems and Cancer, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 11:6300-10. 2005..The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma...
- Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancerKristin K Zorn
National Cancer Institute, Bethesda, MD 20892, USA
Clin Cancer Res 11:6422-30. 2005..This study compares the gene expression profiles of analogous histologic subtypes of cancers of the ovary and endometrium using the same genomic platform to determine the similarities and differences between these tumors...
- Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analysesHiroshi Tsuda
Department of Obstetrics and Gynecology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 11:6880-8. 2005..Genetic changes in this group of cancer have not been thoroughly explored. Identification of these changes may provide us new therapeutic targets to treat this disease...
- Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovaryTomas Bonome
Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Res 65:10602-12. 2005..Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype...
- Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importanceFred W Wamunyokoli
Cell and Cancer Biology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 12:690-700. 2006..To elucidate the molecular mechanisms contributing to the unique clinicopathologic characteristics of mucinous ovarian carcinoma, global gene expression profiling of mucinous ovarian tumors was carried out...
- Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal disseminationAnalisa Difeo
Department of Human Genetics, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, New York 10029, USA
Clin Cancer Res 12:3730-9. 2006..We investigated the role of the KLF6 tumor suppressor gene and its alternatively spliced isoform KLF6-SV1 in epithelial ovarian cancer (EOC)...
- Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell linesPhilip L Lorenzi
Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
Mol Cancer Ther 7:3123-8. 2008..These findings provide rationale for evaluation of ASNS protein expression as a predictive biomarker of clinical L-ASP activity in ovarian cancer...